Materias dentro de su búsqueda.
Mostrando 601 - 620 Resultados de 1,163 Para Buscar 'The Agency', tiempo de consulta: 0.03s Limitar resultados
  1. 601
    Clinical review report Fluocinolone acetonide intravitreal implant (Iluvien) (Knight therapeutics inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  2. 602
    Clinical review report Emtricitabine/tenofovir alafenamide fumarate (Descovy)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  3. 603
    Clinical review report Edoxaban (Lixiana)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  4. 604
    Clinical review report Dolutegravir (Tivicay)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  5. 605
    Clinical review report Dapagliflozin (Forxiga)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  6. 606
    Clinical review report Cysteamine delayed-release capsules (Procysbi) Horizon Pharma Ireland Ltd
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  7. 607
    Clinical review report Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops) (Recordati Rare Diseases Canada Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  8. 608
    Clinical review report Apomorphine (Movapo) (Paladin Labs, Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  9. 609
    CADTH reimbursement recommendation : Hoffmann-La Roche Ltd. : indication: bleeding prevention, hemophilia A (congenital factor VIII deficiency). Emicizumab (Hemlibra)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  10. 610
    CADTH Canadian drug expert committee recommendation (final) : indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol (Cimzia -- UCB Canada Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  11. 611
    CADTH Canadian Drug Expert Committee recommendation : indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone (MDK-Nitisinone - )
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  12. 612
    CADTH Canadian Drug Expert Committee final recommendation Tiotropium/Olodaterol (Inspiolto Respimat - Boehringer Ingelheim Canada Ltd.) indication : chronic obstructive pulmonary disease
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  13. 613
    CADTH Canadian Drug Expert Committee final recommendation Tesamorelin (Egrifta -- Theratechnologies Inc.) indication : HIV-associated lipohypertherapy
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  14. 614
    CADTH Canadian Drug Expert Committee final recommendation Propiverine hydrochloride (Mictoryl/Mictoryl Pediatric--Duchesnay Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  15. 615
    CADTH Canadian Drug Expert Committee final recommendation Emtricitabine / tenofovir alafenamide (Descovy -- Gilead Sciences Canada, Inc.) indication : HIV-1 infection
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  16. 616
    CADTH Canadian Drug Expert Committee final recommendation Edoxaban : Lixiana-Servier Canada Inc. : indication : venous thromboembolic events
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  17. 617
    CADTH Canadian Drug Expert Committee final recommendation Dapagliflozin (Forxiga -- AstraZeneca Canada Inc.) indication : type 2 diabetes
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  18. 618
    CADTH Canadian Drug Expert Committee final recommendation Canagliflozin and metformin hydrochloride (Invokamet -- Janssen Inc.) : type 2 diabetes mellitus
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  19. 619
    CADTH Canadian Drug Expert Committee final recommendation : indication: asthma. Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.)
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico
  20. 620
    Axicabtagene ciloleucel for large B-cell lymphoma Recommendations
    “…Canadian Agency for Drugs and Technologies in Health…”
    Libro electrónico

Herramientas de búsqueda: